Forest plot meta-analysis of the impact of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations on changes in.

Slides:

Advertisements

Similar presentations

Effects of respiratory rate and tidal volume on evaporative loss at constant intrapulmonary perfluorocarbon volume (10 mL·kg−1) and positive end-expiratory.

Advertisements

Pulmonary response in sarcoidosis

Volume 149, Issue 5, Pages (May 2016)

The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease.

Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.

Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

The values for the provoking dose of mannitol to cause a 15% decrease (PD15) in forced expiratory volume in 1 s (FEV1) showing the different levels of.

Immunostaining for lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) adduct in the lungs of smokers with and without chronic obstructive pulmonary.

A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.

Change from baseline following beclomethasone/formoterol and placebo in a) platelet–monocyte aggregate formation, b) P-selectin expression and c) platelet.

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.

Schematic representation of breathing levels during positive expiratory pressure in an obstructed patient. Schematic representation of breathing levels.

Changes of a) spirometric, plethysmographic, and b) impedance data at 5 Hz induced by bronchodilator in flow limited (□) and nonflow limited (▓) patients.

Kaplan–Meier analysis of survival over 2 years of treatment with riociguat in the CHEST-2 study [54]. Kaplan–Meier analysis of survival over 2 years of.

Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to exacerbation history (intent-to-treat.

Schematic representation of the current evidence for the association of cadmium exposure with smoking-related lung disease including chronic obstructive.

A–f) Respiratory mechanical measurements during incremental cycle exercise in patients with moderate chronic obstructive pulmonary disease (COPD) and age-matched.

A) Healthcare utilisation, b) short form (SF)-12 scores and c) work productivity and activity impairment in patients with asthma (▓) and diabetes (▪) in.

Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration.

Forest plots of the correlation between high-resolution computed tomography (HRCT) scores and pulmonary function test values. Forest plots of the correlation.

Benefit–risk balance and its individual determinants with personalised chronic obstructive pulmonary disease (COPD) treatment choices. Benefit–risk balance.

Positron emission tomography scan in the axial plane performed in June 2007 showing intense and homogeneous increased uptake of 18-fluorodeoxyglucose within.

Design of adult and paediatric studies investigating the efficacy and tolerability of ivacaftor [16, 17]. Design of adult and paediatric studies investigating.

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to previous chronic obstructive pulmonary.

Forest plot comparison of mucolytics versus placebo for the number of exacerbations per patient per month. Forest plot comparison of mucolytics versus.

Post-bronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio in subjects aged >50 yrs. Post-bronchodilator forced expiratory.

Effect of omalizumab on change from baseline (B) in a) total asthma symptom score, b) total rhinitis symptom score, and c) combined asthma and rhinitis.

Relationship between bronchodilator response of physiological parameters and concentration of interleukin (IL)-8 in epithelial lining fluid (ELF). Relationship.

A) Cumulative count and b) percent cumulative use of the different pulmonary function test (PFT) measures as longitudinal outcomes for systemic sclerosis-associated.

Receiver operating characteristic (ROC) curves (area under the curve (AUC) (95% CI)) for FACED (forced expiratory volume in 1 s, age, chronic colonisation.

A) Measurement of the right atrial a) area and b) long axis for calculation of right atrial volume. c) Measurement of the left ventricular eccentricity.

Comparison between prediction equations from Wang et al

Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.

Recordings of quiet tidal breathing at rest, followed by maximal expiration then inspiration. Recordings of quiet tidal breathing at rest, followed by.

Physician perspectives on the most useful methods for monitoring α1-antitrypsin deficiency in the clinical trial setting versus clinical practice. Physician.

Scatter plot of body mass index (BMI) versus forced expiratory volume in the first second (FEV1), and linear correlation lines for normal spirometry and.

Forest plot of the a) sensitivity and b) specificity of different pulmonary function test screening algorithms for the presence of systemic sclerosis-associated.

Change in physiological variables from baseline values a) at rest and b) during exercise after saline infusion and exposition to different β-blocker agents.

Forest plot meta-analysis of the impact of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations on a) St George's.

Impact of dose adjustment in case of adverse drug reaction (ADR; includes dose interruption and/or reduction). a) No dose adjustment and b) dose adjustment.

Overall forest plot from meta-analysis carried out in 11 studies a) assessing the relative risk of adverse events; and subgroup analysis performed on studies.

Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)

A) Forced expiratory volume in 1 s (FEV1) and b) 6-min walk test (6MWT) distance by bronchiectasis in any lobe/vascular pruning in the lower lobes groups.

Cumulative mortality over 60 months in patients with α1-antitrypsin deficiency and an initial forced expiratory volume in 1 s

A) Tidal volume (VT) (presented as % predicted of vital capacity (VC)), b) breathing frequency (Fb), c) dynamic inspiratory capacity (IC) and d) inspiratory.

Forest plot from meta-analysis carried out on four studies including high-dose N-acetylcysteine (NAC) treatment a) assessing the relative risk of chronic.

Lung function adjusted for body length and gestational age in male and female premature infants. Lung function adjusted for body length and gestational.

Adjusted mean±se response in peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) at week 24, following once-daily tiotropium Respimat.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.

Risk ratio (RR) and number needed to treat (NNT) are time-dependent measures. a) When an intervention is associated with constant relative risk reduction.

Single photon emission computed tomography ventilation images of a female asthmatic at a, b) baseline and c, d) post-methacholine challenge, at approximately.

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

Technegas® ventilation single photon emission computed tomography images of an asthmatic subject (axial slices) at a) baseline and b) post-methacholine.

A) Operating lung volumes and b) breathing frequency (Fb) during incremental cycle exercise in patients with moderate chronic obstructive pulmonary disease.

24-h blood pressure profile after a, d) one night of intermittent hypoxia (IH) exposure, b, e) 13 nights IH exposure and c, f) 5 days after cessation of.

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.

Survival estimates of patients in REVEAL using Kaplan–Meier estimates stratified by newly versus previously diagnosed patients and survival estimated by.

Study design for ECLIPSE (VX-659 triple combination) and AURORA (VX-445 triple combination) phase 3 studies. Study design for ECLIPSE (VX-659 triple combination)

Correlation between leg fluid volume (LFV) displacement measured by electrical impedance and apnoea/hypopnoea index (AHI) in non-obese obstructive sleep.

Tracing of tidal breathing followed by an inspiratory manoeuvre to total lung capacity (TLC) to record inspiratory capacity (IC), followed by a full expiration.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Interrelationships are shown between exertional dyspnoea intensity and a) minute ventilation (V′E) and b) the tidal volume (VT)/inspiratory capacity (IC)

Presentation transcript:

Forest plot meta-analysis of the impact of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations on changes in trough forced expiratory volume in 1 s (FEV1) at 3, 6 and 12 months. Forest plot meta-analysis of the impact of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations on changes in trough forced expiratory volume in 1 s (FEV1) at 3, 6 and 12 months. Data are presented as mean difference (95% CI) versus monocomponents. Luigino Calzetta et al. Eur Respir Rev 2017;26:160043 ©2017 by European Respiratory Society